Avalo Therapeutics (AVTX) Depreciation & Amortization (CF) (2017 - 2026)

Avalo Therapeutics (AVTX) has 13 years of Depreciation & Amortization (CF) data on file, last reported at $17000.0 in Q1 2026.

• Quarterly Depreciation & Amortization (CF) fell 87.41% year-over-year to $17000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $226000.0 (down 16.3% YoY) and the FY2025 annual result came in at $344000.0, up 103.55% from the prior year.
• Depreciation & Amortization (CF) rose to $17000.0 in Q1 2026, from $16000.0 in the prior quarter.
• In the past five years, Depreciation & Amortization (CF) ranged from a high of $135000.0 in Q1 2025 to a low of $16000.0 in Q4 2025.
• A 5-year average of $50235.3 and a median of $35000.0 in 2022 frame the typical range for Depreciation & Amortization (CF).
• Annual changes were most pronounced in 2022 — Depreciation & Amortization (CF) sank 93.42% — and 2025, when it jumped 306.06%.
• Tracing AVTX's Depreciation & Amortization (CF) over 5 years: stood at $35000.0 in 2022, then advanced by 22.86% to $43000.0 in 2023, then surged by 58.14% to $68000.0 in 2024, then plunged by 76.47% to $16000.0 in 2025, then advanced by 6.25% to $17000.0 in 2026.
• The last three Depreciation & Amortization (CF) figures came in at $17000.0 (Q1 2026), $16000.0 (Q4 2025), and $59000.0 (Q3 2025), per Business Quant data.